|
|
LP-GMP |
|
Vaxjo ID |
380 |
|
Vaccine Adjuvant Name |
LP-GMP |
|
Alternative Names |
LP-GMP refers to the combination of LP1569 (a TLR2 agonist) and c-di-GMP (a STING agonist). |
|
Adjuvant VO ID |
VO_0005662
|
|
Description |
LP-GMP is a novel adjuvant combination designed to enhance immune responses by promoting Th1 and Th17 cells, leading to sustained protective immunity against Bordetella pertussis. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
A novel adjuvant combination (called LP-GMP), comprising c-di-GMP, an intracellular receptor stimulator of interferon genes (STING) agonist, and LP1569, a TLR2 agonist from B. |
|
Structure |
It is a combination of two components: LP1569 (a TLR2 agonist) and c-di-GMP (a STING agonist). |
|
Preparation |
LP-GMP is prepared by combining LP1569 and c-di-GMP, which synergistically enhance immune responses when used as an adjuvant with vaccines. |
|
Function |
Current acellular pertussis (aP) vaccines induce strong antibody and Th2 responses but fail to protect against nasal colonization and transmission of Bordetella pertussis. Furthermore, immunity wanes rapidly after immunization. We have developed a novel adjuvant combination (called LP-GMP), comprising c-di-GMP, an intracellular receptor stimulator of interferon genes (STING) agonist, and LP1569, a TLR2 agonist from B. pertussis, which synergistically induces production of IFN-尾, IL-12 and IL-23, and maturation of dendritic cells. Parenteral immunization of mice with an experimental aP vaccine formulated with LP-GMP promoted Th1 and Th17 responses and conferred protection against lung infection with B. pertussis. Intranasal immunization with the same aP vaccine-induced potent B. pertussis-specific Th17 responses and IL-17-secreting respiratory tissue-resident memory (TRM) CD4 T cells, and conferred a high level of protection against nasal colonization as well as lung infection, which was sustained for at least 10 months. Furthermore, long-term protection against nasal colonization with B. pertussis correlated with the number of IL-17-secreting TRM cells in nasal tissue. Our study has identified an approach for inducing IL-17-secreting TRM cells that sustain sterilizing immunity against nasal colonization of mice with B. pertussis, and could form the basis of a third generation pertussis vaccine for humans. |
|
Safety |
The article indicates that LP-GMP does not induce inflammatory cytokines in the olfactory bulb or brain, suggesting a favorable safety profile compared to other adjuvants. |
| References |
Allen et al., 2018: Allen AC, Wilk MM, Misiak A, Borkner L, Murphy D, Mills KHG. Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting T(RM) cells. Mucosal immunology. 2018; 11(6); 1763-1776. [PubMed: 30127384].
|
|
